BT 2077 | 2013
Biotechnology
NORTH AMERICAN DRUG DELIVERY TECHNOLOGIES MARKET (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts to 2017
Report Description Table of Contents List of Tables Sample Tables Related Reports About MarketsandMarkets
MarketsandMarkets North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252, U.S. Tel. No.: 1-888-600-6441 Email: sales@marketsandmarkets.com Website: www.marketsandmarkets.com
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Report Description Key Take-aways •
Definition, description, and forecast of the North American drug delivery technologies market
•
Analysis of the market structure, along with forecast of the various segments and sub-segments of the North American drug delivery technologies market
•
Detailed information regarding major market trends and factors driving or inhibiting the growth of the North American drug delivery technologies market and its sub-segments
•
Strategic analysis of each submarket with respect to individual growth trends and contribution to the North American drug delivery technologies market
•
Analysis of the opportunities in the market for stakeholders by identifying high growth segments
•
Forecasting revenue of the market segments with respect to two main geographies, namely, the U.S. and Canada
•
Strategic profiling of key players (vendors) and comprehensively analyzing their recent developments, financials, and strategies
•
Tracking and analyzing competitive developments such as alliances, joint ventures, mergers and acquisitions, new product developments, and research and development in the North American drug delivery technologies industry
Report Overview Patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE) is more expensive and time consuming compared to a novel drug delivery technology. Therefore, in recent years, several pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in the near future.
delivery technologies. On the contrary, many other companies still rely on specialty companies engaged in the development of drug delivery technologies. High level of competition and increasing need for outsourcing has resulted in the drug delivery market to be fragmented, with several small companies developing novel drug delivery technologies for niche therapeutic applications. The North American drug delivery market is largely dominated by the U.S. (accounting for about xx% of the overall market). The well established pharmaceutical industry in the U.S., healthcare reforms, and favorable changes in the FDA review process are the key drivers for the U.S. drug delivery market. The Canadian market is being propelled by low cost drug manufacturing and the rise in the number of drug delivery formulations and devices.
The North American drug delivery market was estimated to be worth $xx billion in 2012, and is expected to register a CAGR of xx% between 2012 and 2017. Based on the route of administration, the drug delivery market has been classified as oral, pulmonary, injectable, transdermal, implantable, ocular, nasal, transmucosal, and topical. In 2012, oral drug delivery dominated the market with a share of approximately xx%, followed by pulmonary drug delivery with a xx% share.
Key players in the drug delivery technologies market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton, Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), The Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.), and Valeant Pharmaceuticals (Canada).
The drug delivery technologies that have recently gained importance in North America include orodispersible tablet (ODT), dry powder inhalers, transdermal patches, needle-free injectors, auto and pen injectors, and buccal transmucosal tablets; controlled release is the most widely accepted technology. The use of implantable devices for drug delivery is also on a rise. Big pharmaceutical companies such as Pfizer and Merck have established in-house capabilities for the development of drug
www.marketsandmarkets.com sales@marketsandmarkets.com
2
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Report Description Markets Covered North America drug delivery technologies market, by segment:
•
•
Ocular Drug Delivery § Eye Drops
Oral Drug Delivery
§ Ointment and Gel
§ Controlled Release
§ Others
§ Orodispersible Tablets (ODT) and Taste Masking
•
Nasal Drug Delivery
§ Others
•
§ Nasal Drops
Pulmonary Drug Delivery
§ Nasal Sprays
§ Dry Powder Inhalers
§ Nasal Inhalers
§ Metered Dose Inhalers
§ Others
§ Nebulizers
•
•
Topical Drug Delivery
Transdermal Drug Delivery
§ Liquid Formulations
§ Passive Drug Delivery
§ Semisolid Formulations
o Reservoir System
§ Solid Formulations
o Matrix System
•
Implantable Drug Delivery
§ Active Drug Delivery
•
§ Drug-Eluting Stents
o Iontophoresis
§ Implantable Infusion Pumps
o Microporation
§ Contraceptive Implants
o Others
§ Intravitreal Implants
Injectable Drug Delivery
§ Brachytherapy Seeds
§ Conventional Injection Devices
•
Transmucosal Drug Delivery
o Fillable Syringes
§ Oral (Buccal and Sublingual)
o Prefilled Syringes
§ Others (Rectal and Vaginal)
§ Self-injection Devices
North America drug delivery technologies market, by country:
o Needle-free Injectors o Auto-injectors or Safety Syringe Devices
•
U.S
o Pen Injectors
•
Canada
§ Others
Stake Holders •
Pharmaceutical drug and drug delivery device manufacturers
•
Health insurance players
•
Research and consulting service firms
•
Suppliers and distributors of drugs and drug delivery devices
•
Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMO)
•
Drug delivery technology providers
•
Healthcare service providers (hospitals and independent physicians)
www.marketsandmarkets.com sales@marketsandmarkets.com
3
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Report Description Research Methodology Market Size North American Drug Delivery Technologies Market
North American Drug Delivery Technologies Market
A bottom-up approach was used to calculate the total market. Key data points were collected from public and paid secondary databases and successively validated by primary sources.
Transdermal and Implantable
A bottom-up approach was used to calculate the total market for these segments. Key data points were collected from public and paid secondary databases and successively validated by primary sources.
Oral, Pulmonary, Ocular, Nasal, Topical, Injectable, and Transmucosal
A top-down approach was used to calculate the total market for these segments. Key data points were collected from public and paid secondary databases and successively validated by primary sources.
Market Share Category
Description
Transdermal, Pulmonary, Injectable, and Implantable
Market share for key players has been derived on the basis of secondary data available through paid and unpaid sources, analyzing product portfolios of major companies, and rating them on the basis of performance and quality. These data points were further validated through expert interviews.
Oral, Ocular, Nasal, Topical, and Transmucosal
Market share analysis for these segments has not been derived as these markets are very fragmented. The data related to market share is not available in paid and unpaid secondary sources.
www.marketsandmarkets.com sales@marketsandmarkets.com
4
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Key Data Points from Secondary Sources Market revenue
Company financials, magazines, journals, press releases, paid databases, and MnM analysis data repository International Society of Drug Delivery Sciences and Technology, International Association for Pharmaceutical Technology, American Association of Pharmaceutical Scientists, Drug Development & Delivery Publication, ONdrugDelivery Journal, U.S. FDA (Food and Drug Administration), Health Canada
Market revenue of companies
Annual reports, company website, public databases, and MnM data repository Annual reports, company website, press releases, and MnM data repository
Market dynamics and trends
International Society of Drug Delivery Sciences and Technology, International Association for Pharmaceutical Technology, American Association of Pharmaceutical Scientists, Drug Development & Delivery Publication, ONdrugDelivery Journal, U.S. FDA (Food and Drug Administration), Health Canada
Key Data Points from Primary Sources Parameter Topical drug delivery market Nasal drug delivery market
Data Points Semi-solid formulations constituted 85%-90% of the topical formulations market in 2012. Out of the overall nasal formulations market in 2012, nasal sprays constituted 80%85%, drops ~6%, and inhalers 9%-10%
Assumptions Category
Data Points The same regional percentage split has been assumed for the countries for the base year 2012, based on secondary research:
Geographic Analysis
·
North America: 85%-90%
·
Canada: 10%-15%
Note: These percentages are assumed only for those segments where no data was available through public and paid secondary and primary sources.
www.marketsandmarkets.com sales@marketsandmarkets.com
5
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Chapter Headings ...........................................................................................................................Page No. 1.
Introduction .......................................................................................................................................22 1.1
Key Take-aways ....................................................................................................................................................22
1.2
Report Description ...............................................................................................................................................22
1.3
Markets Covered...................................................................................................................................................24
1.4
Stakeholders .........................................................................................................................................................26
1.5
Research Methodology ........................................................................................................................................26
1.5.1
Market size ......................................................................................................................................................26
1.5.2
Market share ...................................................................................................................................................27
1.5.3
Key data points from secondary sources ........................................................................................................27
1.5.4
Key data points from primary sources.............................................................................................................28
1.5.5
Assumptions....................................................................................................................................................28
2.
Executive Summary ..........................................................................................................................29
3.
Market Overview ................................................................................................................................33 3.1
Introduction ..........................................................................................................................................................34
3.2
Market Segmentation ...........................................................................................................................................34
3.3
Market Dynamics ..................................................................................................................................................36
3.3.1
Drivers ..........................................................................................................................................................36
3.3.1.1 Patent cliff and increased competition to increase adoption rate.............................................................36 3.3.1.2 Improving patient compliance and acceptability, an impetus to the drug delivery systems market .........37 3.3.1.3 Increasing focus on pediatric and geriatric patients to boost the growth .................................................38 3.3.1.4 Increasing incidence of chronic diseases in North America to enhance demand ....................................38 3.3.2
Restraints ........................................................................................................................................................39
3.3.2.1 Drug failures and recalls mar market growth ...........................................................................................39 3.3.2.2 Technical barriers restrict growth .............................................................................................................40 3.3.3
Opportunities ...................................................................................................................................................41
3.3.3.1 Collaborations between pharmaceutical companies and drug delivery firms ..........................................41 3.3.3.2 Self-administration and home care drug delivery devices........................................................................42 3.3.3.3 Expanding therapeutic applications of drug delivery technologies...........................................................43 3.3.4
Targeted drug delivery.....................................................................................................................................43
3.3.4.1 Passive systems contribute 60% to the targeted drug delivery market....................................................44
www.marketsandmarkets.com sales@marketsandmarkets.com
6
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Chapter Headings ...........................................................................................................................Page No. 3.3.4.2 Active targeted drug delivery has major applications in cancer therapy ..................................................44 3.3.4.3 Companies focus on novel targeted drug delivery ...................................................................................44 3.3.5
Burning issues.................................................................................................................................................45
3.3.5.1 Striking right partnerships ........................................................................................................................45 3.3.5.2 Improving the bio availability of drugs ......................................................................................................46 3.4
Regulatory Environment ......................................................................................................................................47
3.4.1
Stringent regulations for pharmaceutical drugs in North America ...................................................................47
3.4.1.1 The approval process is complex, time-consuming, and expensive ........................................................47 3.4.2
Effect of the U.S. Healthcare reforms on the drug delivery industry ...............................................................48
3.4.2.1 Drug delivery companies to benefit from the Affordable Care Act (ACA) reform in the long run..............48 3.4.3 3.5
Regulations related to the approval of controlled release drugs .....................................................................48
Porter’s Five Forces Analysis .............................................................................................................................49
3.5.1
Threat of new entrants ....................................................................................................................................50
3.5.2
Threat of substitutes........................................................................................................................................50
3.5.3
Competitor’s rivalry .........................................................................................................................................50
3.5.4
Bargaining power of suppliers .........................................................................................................................51
3.5.5
Bargaining power of buyers.............................................................................................................................51
3.6
Value Chain Analysis............................................................................................................................................52
3.7
Market Share Analysis .........................................................................................................................................53
3.7.1
Pulmonary drug delivery..................................................................................................................................53
3.7.1.1 U.S. ..........................................................................................................................................................53 3.7.1.2 Canada.....................................................................................................................................................55 3.7.2
Transdermal drug delivery...............................................................................................................................55
3.7.2.1 U.S. ..........................................................................................................................................................55 3.7.2.2 Canada.....................................................................................................................................................57 3.7.3
Injectable drug delivery devices ......................................................................................................................58
3.7.3.1 U.S. ..........................................................................................................................................................58 3.7.3.2 Canada.....................................................................................................................................................60 3.7.4
Implantable drug delivery ................................................................................................................................61
3.7.4.1 U.S. ..........................................................................................................................................................61 3.7.4.2 Canada.....................................................................................................................................................62 3.7.5
Other drug delivery segments .........................................................................................................................63
www.marketsandmarkets.com sales@marketsandmarkets.com
7
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Chapter Headings ...........................................................................................................................Page No. 4.
North America Drug Delivery Market, by Technology....................................................................65 4.1
Introduction...........................................................................................................................................................66
4.1.1
Drug delivery market witnessing technological advancements .......................................................................66
4.2
Opportunity Matrix................................................................................................................................................68
4.3
Oral Drug Delivery ................................................................................................................................................70
4.3.1
Reformulation strategies & establishing in-house capabilities help in significant growth ................................70
4.3.2
Controlled release ...........................................................................................................................................72
4.3.3
Orodispersible Tablets (ODT) and Taste Masking...........................................................................................75
4.3.4
Others..............................................................................................................................................................76
4.4
Pulmonary Drug Delivery.....................................................................................................................................78
4.4.1
Therapeutic applications of pulmonary delivery ..............................................................................................79
4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity .......................79 4.4.2
Metered Dose Inhalers (MDI) ..........................................................................................................................82
4.4.3
Dry Powder Inhalers (DPI) ..............................................................................................................................83
4.4.4
Nebulizers .......................................................................................................................................................84
4.5
Transdermal Drug Delivery ..................................................................................................................................86
4.5.1
Passive transdermal drug delivery ..................................................................................................................88
4.5.1.1 Matrix system ...........................................................................................................................................90 4.5.1.2 Reservoir system .....................................................................................................................................90 4.5.2
Active transdermal drug delivery .....................................................................................................................91
4.5.2.1 Microporation ...........................................................................................................................................92 4.5.2.2 Iontophoresis............................................................................................................................................93 4.5.2.3 Others ......................................................................................................................................................93 4.6
Injectable Drug Delivery.......................................................................................................................................94
4.6.1
Injectable drug delivery market witnessing developments related to product improvement ...........................94
4.6.2
Conventional injectable drug delivery devices ................................................................................................97
4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices .................97 4.6.2.2 Fillable......................................................................................................................................................99 4.6.2.3 Prefilled ..................................................................................................................................................100 4.6.3
Self-injection devices.....................................................................................................................................100
4.6.3.1 Self-injection devices reduce overall treatment cost ..............................................................................101 4.6.3.2 Pen injectors ..........................................................................................................................................103 4.6.3.3 Needle-free injectors ..............................................................................................................................104 4.6.3.4 Auto injectors .........................................................................................................................................105 4.6.4
Others............................................................................................................................................................106
www.marketsandmarkets.com sales@marketsandmarkets.com
8
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Chapter Headings ...........................................................................................................................Page No. 4.7
Ocular Drug Delivery ..........................................................................................................................................108
4.7.1
Eye drops ......................................................................................................................................................110
4.7.2
Ointments and gels........................................................................................................................................111
4.7.3
Others............................................................................................................................................................112
4.8
Nasal Drug Delivery ............................................................................................................................................114
4.8.1
Nasal drug delivery preferred for locally acting drugs and delivery of vaccines ............................................114
4.8.2
Nasal sprays..................................................................................................................................................116
4.8.3
Nasal inhalers................................................................................................................................................118
4.8.4
Nasal drops ...................................................................................................................................................119
4.8.5
Others............................................................................................................................................................120
4.9
Topical Drug Delivery .........................................................................................................................................121
4.9.1
Topical delivery majorly adopted for dermatology drugs ...............................................................................121
4.9.2
Semi-solid formulations .................................................................................................................................124
4.9.3
Liquid formulations ........................................................................................................................................125
4.9.4
Solid formulations..........................................................................................................................................126
4.10
Implantable Drug Delivery .................................................................................................................................128
4.10.1 Drug- eluting stents .......................................................................................................................................130 4.10.2 Implantable infusion pumps...........................................................................................................................132 4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments ...........................................133 4.10.3 Contraceptive implants..................................................................................................................................134 4.10.4 Intravitreal implants .......................................................................................................................................134 4.10.5 Brachytherapy seeds.....................................................................................................................................136 4.11
5.
Transmucosal Drug Delivery .............................................................................................................................138
4.11.1
Oral (buccal and sublingual)..........................................................................................................................140
4.11.2
Others (rectal, vaginal) ..................................................................................................................................142
Geographic Analysis.......................................................................................................................144 5.1
Introduction ........................................................................................................................................................145
5.2
United States.......................................................................................................................................................147
5.2.1
Well-established U.S. Pharmaceutical industry drives the drug delivery market ..........................................147
5.2.2
Favorable changes in the FDA to accelerate drug review and approval processes .....................................148
5.2.3
U.S. Healthcare reforms will impact the drug delivery market.......................................................................148
5.3
Canada ...............................................................................................................................................................159
5.3.1
Insurance coverage favoring the growth of Canadian drug delivery technology market...............................159
5.3.2
Rise in number of approvals and agreements in the Canada drug delivery market .....................................159
www.marketsandmarkets.com sales@marketsandmarkets.com
9
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Table of Contents Chapter Headings ...........................................................................................................................Page No. 6.
Competitive Landscape ..................................................................................................................171 6.1
Introduction ........................................................................................................................................................171
6.1.1
7.
Mergers & acquisitions and agreements & collaborations were the key strategies adopted by players .......172
6.2
Mergers & Acquisitions......................................................................................................................................172
6.3
Agreements, Collaborations, Joint Ventures & Partnerships ........................................................................175
6.4
New Product Launch ..........................................................................................................................................177
6.5
Other Developments...........................................................................................................................................179
Company Profiles ............................................................................................................................187
(Overview, Financials, Products & Services, Strategy, & Developments)* 7.1
3M COMPANY......................................................................................................................................................187
7.2
APTALIS PHARMA, INC......................................................................................................................................194
7.3
BAXTER INTERNATIONAL, INC.........................................................................................................................199
7.4
BECTON, DICKINSON AND COMPANY.............................................................................................................205
7.5
CATALENT PHARMA SOLUTIONS ....................................................................................................................212
7.6
CIMA LABS ........................................................................................................................................................219
7.7
ENDO HEALTH SOLUTIONS, INC......................................................................................................................225
7.8
JOHNSON & JOHNSON, INC. ............................................................................................................................231
7.9
NEKTAR THERAPEUTICS, INC..........................................................................................................................238
7.10
OPTINOSE AS .....................................................................................................................................................242
7.11
PSIVIDA CORPORATION....................................................................................................................................246
7.12
THE DOW CHEMICAL COMPANY......................................................................................................................251
7.13
VALEANT PHARMACEUTICALS........................................................................................................................257
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
www.marketsandmarkets.com sales@marketsandmarkets.com
10
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
List of Tables Table Titles ..............................................................................................................................Page No. 1
North America Drug Delivery Market, by Country, 2010 - 2017 ($Million) ....................................................................31
2
Key Drug Delivery Technology Providers & Marketer Companies................................................................................63
3
North American Drug Delivery Market, by Route of Administration, 2010 - 2017.........................................................67
4
North American Oral Drug Delivery Market, by Technology, 2010 - 2017 ($Million).....................................................71
5
North American Oral Drug Delivery Market, by Country, 2010 - 2017 ($Million) ..........................................................72
6
Controlled Release Drug Delivery Market, by Country, 2010 - 2017 ($Million) ............................................................74
7
ODT & Taste-masking Market, by Country, 2010 - 2017 ($Million)...............................................................................76
8
Other Oral Drug Delivery Technologies Market, by Country, 2010 - 2017 ($Million) ....................................................77
9
North American Pulmonary Drug Delivery Market, by Device Type, 2010 - 2017 ($Million).........................................80
10
North American Pulmonary Drug Delivery Market, by Country, 2010 - 2017 ($Million) ................................................81
11
Comparative Overview of Pulmonary Drug Delivery Devices ......................................................................................81
12
Metered Dose Inhalation Market, by Country, 2010 - 2017 ($Million)...........................................................................83
13
Dry Powder Inhalation Market, by Country, 2010 - 2017 ($Million) ..............................................................................84
14
Nebulizers Market, by Country, 2010 - 2017 ($Million).................................................................................................85
15
North American Transdermal Drug Delivery Market, by Mode of Delivery, 2010 - 2017 ($Million)...............................87
16
North American Transdermal Drug Delivery Market, by Country, 2010 - 2017 ($Million) .............................................88
17
Passive Transdermal Drug Delivery Market, by Technology, 2010 - 2017 ($Million)....................................................89
18
Passive Transdermal Drug Delivery Market, by Country, 2010 - 2017 ($Million) .........................................................90
19
Active Transdermal Drug Delivery Market, by Technology, 2010 - 2017 ($Million).......................................................91
20
Active Transdermal Drug Delivery Market, by Country, 2010 - 2017 ($Million) ............................................................92
21
North American Injectable Drug Delivery Market, by Product Type, 2010 - 2017 ($Billion)..........................................95
22
North American Injectable Drug Delivery Market, by Country, 2010 - 2017 ($Billion) ..................................................96
23
Conventional Injection Devices Market, by Product, 2010 - 2017 ($Billion) .................................................................98
24
Conventional Injection Devices Market, by Country, 2010 - 2017 ($Billion) .................................................................99
25
Self-injection Devices Market, by Product, 2010 - 2017 ($Million) .............................................................................102
26
Self-injection Devices Market, by Country, 2010 - 2017 ($Million) .............................................................................103
27
Other Injectors Market, by Country, 2010 - 2017 ($Million) ........................................................................................107
28
North American Ocular Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) ..............................................109
29
North American Ocular Drug Delivery Market, by Country, 2010 - 2017 ($Million).....................................................110
30
Eye Drop Drug Delivery Market, by Country, 2010 - 2017 ($Million) ..........................................................................111
31
Ointment & Gel Delivery Market, by Country, 2010 - 2017 ($Million) .........................................................................112
32
Other Ocular Drug Delivery Market, by Country, 2010 - 2017 ($Million).....................................................................113
33
North American Nasal Drug Delivery Market, by Formulation, 2010 - 2017 ($Million)................................................115
34
North American Nasal Drug Delivery Market, by Country, 2010 - 2017 ($Million) ......................................................116
35
Nasal Spray Market, by Country, 2010 - 2017 ($Million) ............................................................................................117
www.marketsandmarkets.com sales@marketsandmarkets.com
11
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
List of Tables Table Titles ..............................................................................................................................Page No. 36
Nasal Inhaler Market, by Country, 2010 - 2017 ($Million)...........................................................................................118
37
Nasal Drops Market, by Country, 2010 - 2017 ($Million) ............................................................................................119
38
Other Nasal Delivery Formulations Market, by Country, 2010 - 2017 ($Million).........................................................120
39
North American Topical Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) .............................................123
40
North American Topical Drug Delivery Market, by Country, 2010 - 2017 ($Million) ....................................................124
41
Semi-solid Topical Formulation Market, by Country, 2010 - 2017 ($Million)...............................................................125
42
Liquid Topical Formulation Market, by Country, 2010 - 2017 ($Million) ......................................................................126
43
Solid Topical Formulation Market, by Country, 2010 - 2017 ($Million)........................................................................127
44
North American Implantable Drug Delivery Market, by Device, 2010 - 2017 ($Million)..............................................129
45
Implantable Drug Delivery Market, by Country, 2010 - 2017 ($Million) ......................................................................130
46
Drug-eluting Stents Market, by Country, 2010 - 2017 ($Million) .................................................................................132
47
Implantable Infusion Pumps Market, by Country, 2010 - 2017 ($Million) ...................................................................133
48
Contraceptive Implants Market, by Country, 2010 - 2017 ($Million) ...........................................................................134
49
Intravitreal Implants Market, by Country, 2010 - 2017 ($Million) ................................................................................135
50
Brachytherapy Seeds Market, by Country, 2010 - 2017 ($Million) .............................................................................137
51
North American Transmucosal Drug Delivery Market, by Mucosa Type, 2010 - 2017 ($Million)................................139
52
North American Transmucosal Drug Delivery Market, by Country, 2010 - 2017 ($Million).........................................140
53
Oral Transmucosal Drug Delivery Market, by Country, 2010 - 2017 ($Million)...........................................................141
54
Other Transmucosal Drug Delivery Technologies Market, by Country, 2010 - 2017 ($Million)...................................142
55
North American Drug Delivery Market, by Country, 2010 - 2017 ($Million) ................................................................146
56
U.S.: Drug Delivery Technologies Market, by Route of Administration, 2010 - 2017 ($Million) ..................................149
57
U.S.: Oral Drug Delivery Market, by Technology, 2010 - 2017 ($Million)....................................................................150
58
North American Pulmonary Drug Delivery Market, by Device Type, 2010 - 2017 ($Million).......................................151
59
U.S.: Transdermal Drug Delivery Market, by Mode of Delivery, 2010 - 2017 ($Million)..............................................152
60
U.S.: Injectable Drug Delivery Market, by Technology, 2010 - 2017 ($Million) ...........................................................153
61
U.S.: Ocular Drug Delivery Market, by Formulation,2010 - 2017 ($Million)................................................................154
62
U.S.: Nasal Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) ................................................................155
63
U.S.: Topical Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) ..............................................................156
64
U.S.: Implantable Drug Delivery Market, by Device Type, 2010 - 2017 ($Million) ......................................................157
65
U.S.: Transmucosal Drug Delivery Market, by Mucosa Type, 2010 - 2017 ($Million).................................................158
66
Canada: Drug Delivery Market, by Route of Administration, 2010 - 2017 ($Million) ..................................................161
67
Canada: Oral Drug Delivery Market, by Technology, 2010 - 2017 ($Million) ..............................................................162
68
Canada: Pulmonary Drug Delivery Market, by Device Type, 2010 - 2017 ($Million)..................................................163
69
Canada: Transdermal Drug Delivery Market, by Mode of Delivery, 2010 - 2017 ($Million) ........................................164
70
Canada: Injectable Drug Delivery Market, by Technology, 2010 - 2017 ($Million) .....................................................165
www.marketsandmarkets.com sales@marketsandmarkets.com
12
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
List of Tables Table Titles ..............................................................................................................................Page No. 71
Canada: Ocular Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) .........................................................166
72
Canada: Nasal Drug Delivery Market, by Formulation, 2010 - 2017 ($Million) ..........................................................167
73
Canada: Topical Drug Delivery Market, by Formulation, 2010 - 2017 ($Million).........................................................168
74
Canada: Implantable Drug Delivery Market, by Device Type, 2010 - 2017 ($Million) ................................................169
75
Canada: Transmucosal Drug Delivery Market, by Mucosa Type, 2010 - 2017 ($Million) ...........................................170
76
Mergers & Acquisitions, 2011 - 2013 ..........................................................................................................................173
77
Agreements, Collaborations, Joint Ventures & Partnerships, 2011 -2013 ..................................................................176
78
New Product Launch, 2010 - 2012 .............................................................................................................................178
79
Other Developments, 2010 - 2013 .............................................................................................................................179
80
3M Company: Total Revenue, by Segment, 2009 - 2011 ($Million)............................................................................189
81
3M Company: Total Revenue, by Geography, 2009 - 2011 ($Million) ........................................................................190
82
Baxter International: Total Revenue, by Segment, 2010 - 2012 ($Million) .................................................................201
83
Baxter International: Medical Products Total Revenue, 2010 - 2012($Million) ...........................................................201
84
Baxter International: Total Revenue, by Geography, 2010 - 2012 ($Million) ..............................................................202
85
Becton, Dickinson: Total Revenue, by Segment, 2010 - 2012 ($Million) ....................................................................206
86
Becton, Dickinson: Medical Division Total Revenue, by Segment, 2010 - 2012 ($Million) .........................................207
87
Becton, Dickinson: Total Revenue, by Geography, 2010 - 2012($Million)..................................................................207
88
Catalent Pharma Solutions: Total Revenue, by Segment, 2009 - 2011 ($Million) ......................................................213
89
Teva Pharmaceutical Industries Limited: Total Revenue, by Segment, 2010 - 2012 ($Million) ..................................221
90
Teva Pharmaceutical Industries Limited: Total Revenue, by Geography, 2010 - 2012 ($Million) ...............................222
91
Endo Health Solutions, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) .....................................................227
92
Johnson & Johnson, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) .........................................................233
93
Johnson & Johnson, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million) ......................................................233
94
The Dow Chemical Company: Total Revenue, by Segment, 2010 - 2012 ($Million) ..................................................252
95
Valeant Pharmaceuticals: Total Revenue, by Geography, 2010 - 2012 ($Million) ......................................................258
www.marketsandmarkets.com sales@marketsandmarkets.com
13
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
List of Figures Figure Titles ............................................................................................................................Page No. 1
North America Drug Delivery Market, by Route of Administration (2012).....................................................................30
2
Drug Delivery Market Segmentation.............................................................................................................................34
3
Market Dynamics ..........................................................................................................................................................37
4
Porter’s Five Forces Analysis for Drug Delivery Market ...............................................................................................49
5
Value Chain Analysis ....................................................................................................................................................52
6
U.S. Pulmonary Drug Delivery: Market Share Analysis, by Key Player, 2012..............................................................54
7
Canada Pulmonary Drug Delivery: Market Share Analysis, by Key Player, 2012 ........................................................55
8
U.S. Transdermal Drug Delivery: Market Share Analysis, by Key Player, 2012 ...........................................................56
9
Canada Transdermal Drug Delivery: Market Share Analysis, by Key Player, 2012 .....................................................57
10
U.S. Injectable Drug Delivery Devices Market, by Key Players, 2012..........................................................................58
11
Canada Injectable Drug Delivery Devices Market, by Key Players, 2012 ....................................................................60
12
U.S. Implantable Drug Delivery: Market Share Analysis, by Key Player, 2012 ............................................................61
13
Canada Implantable Drug Delivery: Market Share Analysis, by Key Player, 2012.......................................................62
14
Opportunity Matrix: North America Drug Delivery Market (2012) .................................................................................68
15
Oral Drug Delivery Market Share (2012) ......................................................................................................................71
16
Key Growth Strategies, 2010 - 2013 ..........................................................................................................................171
17
3M Company: Total Revenue and R&D Expenses, 2009 - 2011 ($Million) ................................................................188
18
Aptalis Pharma, Inc.: Total Revenue and R&D Expenses, 2009 - 2011 ($Million)......................................................195
19
Baxter International: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ......................................................200
20
Becton, Dickinson: Total Revenue and R&D Expenditure, 2010 - 2012 ($Million) .....................................................206
21
Catalent Pharma Solutions: Total Revenue and R&D Expenses, 2009 - 2011 ($Million) ...........................................213
22
Teva Pharmaceutical Industries Limited: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) .......................220
23
Endo Health Solutions, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ..........................................226
24
Johnson & Johnson, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ..............................................232
25
Nektar Therapeutics, Inc.: Total Revenue and R&D Expenses, 2009 - 2011 ($Million)..............................................239
26
Psivida Corporation: Total Revenue, 2009 - 2011 ($Million).......................................................................................247
27
The Dow Chemical Company: Total Revenue and R&D Expenses, 2010 - 2012 ($Million).......................................252
28
Valeant Pharmaceuticals: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ..............................................258
www.marketsandmarkets.com sales@marketsandmarkets.com
14
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Sample Tables North American Drug Delivery Market, By Route of Administration, 2010 – 2017 Route of Administration
2010
2011
2012
2017
CAGR% (2012-2017)
Oral Pulmonary
s e l b a T e l p m
Transdermal Injectable Ocular Nasal
Sa
Topical Implantable Transmucosal Total
North American Oral Drug Delivery Market, By Technology, 2010 – 2017 ($Million) Technology
s e l b a T e pl
2010
2011
Controlled Release ODT and Taste Masking Others
2012
2017
CAGR% (2012-2017)
Sam
Total
North American Oral Drug Delivery Market, by Country, 2010 – 2017 ($Million) Device Type
s e l b a T e l mp
2010
U.S. Canada Total
www.marketsandmarkets.com sales@marketsandmarkets.com
2011
Sa
15
2012
2017
CAGR% (2012-2017)
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
Disclaimer MarketsandMarketsDisclaimer: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customers' internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.
MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets' research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users.
All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com
Copyright Š 2013 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
www.marketsandmarkets.com sales@marketsandmarkets.com
16
North American Drug Delivery Technologies Market
BT 2077
– Forecasts To 2017
2013
About MarketsandMarkets We publish about 400 reports a year across 13 main industries. the reports are exhaustive, detailing about 50 micro markets and product segments, and featuring about 80 to 100 market data summary tables, 50 short company profiles, a five-level market breakdown, overviews of more than 300 patents, as well as analyses of the strategic and competitive landscape.
Our clients value our reports especially for the market insight we provide along with the market numbers. Our teams of specialized market analysts and domain experts work within a structured research process to deliver well-analyzed market reports to Fortune 1000 companies globally.
Click here to learn more about us
Related Reports Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, AutoInjectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017 Patent expiry of major blockbuster drugs is a foremost concern for pharmaceutical companies. Developing a new chemical entity (NCE) is more expensive and time consuming than developing a novel drug delivery technology. Therefore, in recent years many pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in near future.
Report code: BT 1539
Injectable Drug Delivery Market by Formulations, Devices & Therapeutics Global Forecasts to 2017 Globally, injectable medications form the second most preferred class of drugs, with oral route of administration leading the global pharma market. Injectable drug delivery devices have evolved from traditional needles and syringes to recently developed needle-free injectors. The market has evidenced a shifting trend from administration of injections in clinician settings to home care settings, which has resulted in increasing the focus of industry players towards the development of user friendly and patient compliant devices.
Report code: BT 1862
www.marketsandmarkets.com sales@marketsandmarkets.com
17